Skip to main content

Topical Calcineurin Inhibitors

Topical calcineurin inhibitors (TCIs) — tacrolimus (0.03% and 0.1% ointment) and pimecrolimus (1% cream) — serve primarily as second-line, steroid-sparing anti-inflammatory agents in urology and urogynecology. Their established roles are in genital lichen sclerosus, vulvar / penile lichen planus, Zoon balanitis, and other anogenital inflammatory dermatoses.[1][2][3] A novel investigational application is intravesical tacrolimus for refractory IC/BPS.

The defining advantage over topical corticosteroids is no risk of skin atrophy — a critical property in the thin, sensitive anogenital skin, particularly for the indefinite maintenance that chronic LS and LP require.[3][4]

For related agents, see High-potency topical corticosteroids, Intralesional corticosteroids, Platelet-rich plasma, Intravesical IC/BPS agents, and the clinical Lichen sclerosus article.

Mechanism​

TCIs inhibit calcineurin, a calcium-dependent phosphatase required for NFAT-mediated T-cell activation. The resulting block suppresses transcription of IL-2, IL-3, IL-4, IFN-γ, and TNF.[5][6] Additional mast-cell stabilization and suppression of histamine release contribute to the antipruritic effect.[7][8]

Critically, TCIs do not affect collagen synthesis and therefore do not cause skin atrophy, striae, telangiectasia, or the rebound effects seen with long-term corticosteroid use — the pharmacologic basis for their role as steroid-sparing maintenance agents in chronic genital dermatoses.[3][4]

Vulvar and anogenital lichen sclerosus — primary indication​

The most extensively studied urogynecologic application.

ACOG Practice Bulletin 224 (2020) — Level B recommendation: TCIs are recommended for LS that does not respond to topical or intralesional corticosteroids, or for patients at risk of steroid-induced skin atrophy.[9]

Evidence​

StudyDesignFinding
Hengge 2006Phase II multicenter (n = 84) — tacrolimus 0.1% BID × 16 wk43% clearance of active LS + 34% partial resolution; significant reduction in lesional area and symptom scores; only 9% recurred during 18-mo follow-up[10]
Funaro 2014 RCTDouble-blind clobetasol 0.05% vs tacrolimus 0.1%Both reduced symptoms; clobetasol significantly more effective for complete absence of signs/symptoms (p = 0.002)[11]
Chi 2011 CochraneSystematic reviewPimecrolimus comparable to clobetasol for symptom relief; less effective for gross clinical improvement[12][13]
Mazzilli 2018Pediatric case series — tacrolimus 0.03%Well-tolerated; significant improvement in itching, pain, and constipation[14]

Clinical position​

TCIs sit as an alternative to ultrapotent corticosteroids, particularly useful for:[15][16]

  • Maintenance therapy after clobetasol induction
  • Steroid-refractory disease
  • Steroid-atrophy concern (long-standing use, thin atrophic skin)
  • Pediatric LS where long-term steroid use is a particular concern

Clobetasol 0.05% ointment remains first-line for induction; TCIs are second-line and steroid-sparing. See High-potency topical corticosteroids for the induction framework.

Penile lichen sclerosus / BXO​

Shieh 2024 J Urol systematic review — topical corticosteroids remain the mainstay of conservative management for penile / urethral LS, with tacrolimus supported as an alternative or adjuvant when escalation is needed.[17]

In pediatric BXO, circumcision remains definitive; topical immunomodulators as adjuncts may decrease the incidence of recurrent meatal stenosis.[18]

Kim 2012 — tacrolimus in anogenital LS: 90% objective response (50% complete, 40% partial). However, relapse was common (6/9) during long-term follow-up, underscoring the need for ongoing maintenance therapy.[19]

Vulvar and genital lichen planus​

ACOG Level B: TCIs for LP resistant to topical corticosteroid therapy.[9]

  • Byrd 2004 — retrospective data on tacrolimus for recalcitrant vulvar LP showed effective symptom control, but benefits were not sustained after discontinuation — ongoing maintenance is required[20]
  • Goldstein 2009 — both tacrolimus and pimecrolimus supported as effective and well-tolerated second-line options for genital LP[3]

Other anogenital dermatoses​

ConditionTCI roleEvidence
Plasma cell (Zoon) balanitisTacrolimus 0.1% — good results within 4 weeksKyriakou 2014 series (n = 9)[21][22]
Genital psoriasisTacrolimus / pimecrolimus — up to 71% clear or almost clear at 8 weeksAmiri 2023 SR (24 studies)[23][24]
Perianal eczemaTacrolimus 0.1% BID × 2 weeksSchauber 2009 — clinical improvement in all patients[25]
Resistant anogenital pruritusTacrolimus — likely via TRPV1 activationYosipovitch 2013[26]

Intravesical tacrolimus for IC/BPS — investigational​

A novel off-label application under active investigation.

  • Mishra 2019 pilot (n = 24 intractable IC/BPS) — tacrolimus dissolved in DMSO/sterile water instilled intravesically; improvement in 54% (13/24) over 6–63-month follow-up. Serum tacrolimus levels remained safe; no significant systemic AEs[27]
  • 2025 global consensus lists tacrolimus among immunotherapies for IC/BPS, alongside cyclosporine[28]

Cyclosporine A has stronger evidence in IC/BPS based on Di 2021 network meta-analysis and Giannantoni 2012 European Urology systematic review — intravesical tacrolimus remains early-stage off-label pending controlled trials.[29][30]

See Intravesical IC/BPS agents for the complete instillation armamentarium.

Genital graft-versus-host disease — caution​

  • Choi 2001 case series (n = 18 chronic cutaneous GVHD) — topical tacrolimus showed response in ~70%[4]
  • Elad 2003 — topical tacrolimus as a novel treatment alternative for cutaneous chronic GVHD[31]
  • Rostagno 2022 scoping review concluded no topical intervention has strong evidence in GVHD — topical therapies serve as adjuncts to systemic treatment[32]

FDA label caution: avoid topical tacrolimus in cutaneous GVHD due to skin-barrier defects that can drive systemic absorption. Toxic tacrolimus levels have been reported when occlusive dressings are used concurrently.[33][34]

Safety​

Adverse effects​

ConcernDetails
Local irritationBurning / stinging / pruritus — most common in first days; subsides with continued use[5][6][7]
FDA Black-Box WarningTheoretical risk of lymphoma / malignancy based on animal systemic-dosing studies; no increased incidence in large prospective cohorts or meta-analyses of topical use[6][4]
No skin atrophyKey advantage over corticosteroids for chronic anogenital use[3]
Systemic absorptionMinimal through intact skin; caution with skin-barrier defects (GVHD, Netherton's), occlusive dressings, or large BSA application[7][33]
Avoid on premalignant / malignant lesionsPer FDA label; CTCL may mimic dermatitis[7]
Sun protectionRecommended during therapy based on photocarcinogenicity data[4]

Tacrolimus vs pimecrolimus​

AgentStrengthPractical differentiators
Tacrolimus ointment 0.03% / 0.1%0.1% is the standard adult dose; 0.03% used in pediatricsStronger immunomodulatory effect; more likely effective in LS, LP, Zoon balanitis; more burning / stinging on application
Pimecrolimus cream 1%Single strengthBetter tolerated (less burning); less effective than clobetasol for gross LS improvement; reasonable for maintenance and mild disease[12][13]

Prescribing summary​

ConditionFirst-lineTCI roleTCI regimenDuration
Lichen sclerosus (vulvar or penile)Clobetasol 0.05% ointmentSecond-line / steroid-sparing maintenanceTacrolimus 0.1% ointment BID after clobetasol induction or as sole agent in steroid-intolerant patientsIndefinite (LS is chronic)[9][10]
Vulvar / genital lichen planusClobetasol 0.05% ointmentSecond-line when steroid-refractoryTacrolimus 0.1% BIDOngoing; symptoms often recur on discontinuation[9][20]
Plasma cell (Zoon) balanitisTrimovate or moderate TCS; circumcision curativeAlternative for recalcitrant / circumcision-declinedTacrolimus 0.1% BID × 4 weeksUntil resolution[21]
Genital psoriasisLow-potency TCSSteroid-sparing maintenanceTacrolimus 0.1% BID or pimecrolimus 1% BIDIntermittent / maintenance[23][24]
Perianal eczemaLow-potency TCSAlternative if corticosteroid refractoryTacrolimus 0.1% BID × 2 weeksShort course[25]
Anogenital pruritus (refractory)Address cause; low-potency TCSAdjunctive for resistant casesTacrolimus 0.1% BIDUntil symptomatic improvement[26]
IC/BPS (refractory)Standard stepwise AUA-guideline careInvestigationalIntravesical tacrolimus (Mishra protocol)Per trial protocol[27]
Cutaneous GVHD (genital)Systemic therapyCaution — risk of systemic absorptionTacrolimus 0.1% — avoid occlusion; monitor levels if usedAdjunct only[33][34]

Evidence Summary​

IndicationEvidence levelKey source
Vulvar LS (general)Level 1 (Cochrane + RCTs)Chi 2011 Cochrane[12]; Funaro 2014[11]; Hengge 2006[10]
Penile LSLevel 2 (SR)Shieh 2024[17]; Kim 2012[19]
Pediatric LSLevel 3Mazzilli 2018[14]
Vulvar lichen planusLevel 3 (retrospective)Byrd 2004[20]; ACOG 224[9]
Plasma cell balanitisLevel 3 (case series)Kyriakou 2014[21]
Genital psoriasisLevel 2 (SR)Amiri 2023[23]
Intravesical tacrolimus for IC/BPSLevel 3 (pilot)Mishra 2019[27]
GVHDLevel 3; FDA cautionChoi 2001[4]; Olson 2014 toxicity report[34]

Clinical Positioning​

  • TCIs are second-line, steroid-sparing agents for chronic anogenital inflammatory dermatoses — their defining feature is no skin atrophy, which is load-bearing for the indefinite maintenance LS and LP require.[3][9]
  • Clobetasol remains first-line for induction in LS and LP; switch to tacrolimus 0.1% BID for long-term maintenance after control is achieved.[11][12]
  • In pediatric LS, TCIs are particularly valuable — Mazzilli 2018 and ACOG both support tacrolimus 0.03% as a steroid-sparing alternative where long-term steroid use is a concern.[9][14]
  • Counsel about application-site burning — the dominant early AE; reassure that it subsides with continued use over 1–2 weeks to improve adherence.[5][6]
  • The FDA black-box warning is largely theoretical — no increased malignancy signal in large real-world cohorts of topical use. Disclose per label but do not refuse therapy on this basis alone.[6]
  • Pimecrolimus is less effective than clobetasol for LS gross improvement — reserve it for mild disease, maintenance, or patients intolerant of tacrolimus burning.[12][13]
  • In Zoon balanitis, circumcision remains curative; tacrolimus is the best-supported non-surgical option for patients declining or unable to undergo circumcision.[21]
  • Intravesical tacrolimus for IC/BPS is investigational (Mishra 2019 — 54% response). Cyclosporine has stronger evidence in this setting; do not default to intravesical tacrolimus outside of trial protocols or refractory-case shared decision-making.[27][29]
  • Avoid topical tacrolimus on broken skin or under occlusion — systemic absorption can reach toxic levels (GVHD case reports). In cutaneous GVHD specifically, the FDA cautions against its use.[33][34]
  • Avoid application on premalignant or malignant lesions. Evaluate unresponsive or atypical vulvar lesions with biopsy before escalating immunomodulatory therapy — CTCL and early vulvar SCC can masquerade as dermatitis or LS.[7][9]
  • Sun protection during treatment is reasonable given photocarcinogenicity signals.[4]

See Also​

References​

1. Cury Martins J, Martins C, Aoki V, et al. "Topical tacrolimus for atopic dermatitis." Cochrane Database Syst Rev. 2015;(7):CD009864. doi:10.1002/14651858.CD009864.pub2

2. Vakharia PP, Silverberg JI. "New and emerging therapies for paediatric atopic dermatitis." Lancet Child Adolesc Health. 2019;3(5):343–353. doi:10.1016/S2352-4642(19)30030-6

3. Goldstein AT, Thaçi D, Luger T. "Topical calcineurin inhibitors for the treatment of vulvar dermatoses." Eur J Obstet Gynecol Reprod Biol. 2009;146(1):22–29. doi:10.1016/j.ejogrb.2009.05.026

4. Choi CJ, Nghiem P. "Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients." Arch Dermatol. 2001;137(9):1202–1206. doi:10.1001/archderm.137.9.1202

5. Eichenfield LF, Tom WL, Berger TG, et al. "Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies." J Am Acad Dermatol. 2014;71(1):116–132. doi:10.1016/j.jaad.2014.03.023

6. Prucha H, Schnopp C, Akdis C, et al. "Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema." Expert Opin Drug Metab Toxicol. 2013;9(11):1507–1516. doi:10.1517/17425255.2013.819343

7. US Food and Drug Administration. Tacrolimus — prescribing information. Updated 2026-04-15.

8. Rallis E, Korfitis C, Gregoriou S, Rigopoulos D. "Assigning new roles to topical tacrolimus." Expert Opin Investig Drugs. 2007;16(8):1267–1276. doi:10.1517/13543784.16.8.1267

9. American College of Obstetricians and Gynecologists. "Diagnosis and management of vulvar skin disorders: ACOG Practice Bulletin No. 224." Obstet Gynecol. 2020;136(1):222–225. doi:10.1097/AOG.0000000000003945

10. Hengge UR, Krause W, Hofmann H, et al. "Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus." Br J Dermatol. 2006;155(5):1021–1028. doi:10.1111/j.1365-2133.2006.07446.x

11. Funaro D, Lovett A, Leroux N, Powell J. "A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus." J Am Acad Dermatol. 2014;71(1):84–91. doi:10.1016/j.jaad.2014.02.019

12. Chi CC, Kirtschig G, Baldo M, et al. "Topical interventions for genital lichen sclerosus." Cochrane Database Syst Rev. 2011;(12):CD008240. doi:10.1002/14651858.CD008240.pub2

13. Chi CC, Kirtschig G, Baldo M, et al. "Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus." J Am Acad Dermatol. 2012;67(2):305–312. doi:10.1016/j.jaad.2012.02.044

14. Mazzilli S, Diluvio L, Di Prete M, et al. "Tacrolimus 0.03% ointment for treatment of paediatric lichen sclerosus: a case series and literature review." J Int Med Res. 2018;46(9):3724–3728. doi:10.1177/0300060518778219

15. De Luca DA, Papara C, Vorobyev A, et al. "Lichen sclerosus: the 2023 update." Front Med. 2023;10:1106318. doi:10.3389/fmed.2023.1106318

16. Borghi A, Corazza M. "Novel therapeutic approaches and targets for treatment of vulvar lichen sclerosus." Curr Pharm Biotechnol. 2021;22(1):99–114. doi:10.2174/1389201021666200516154310

17. Shieh C, Hakam N, Pearce RJ, et al. "Conservative management of penile and urethral lichen sclerosus: a systematic review." J Urol. 2024;211(3):354–363. doi:10.1097/JU.0000000000003804

18. Nguyen ATM, Holland AJA. "Balanitis xerotica obliterans: an update for clinicians." Eur J Pediatr. 2020;179(1):9–16. doi:10.1007/s00431-019-03516-3

19. Kim GW, Park HJ, Kim HS, et al. "Topical tacrolimus ointment for the treatment of lichen sclerosus, comparing genital and extragenital involvement." J Dermatol. 2012;39(2):145–150. doi:10.1111/j.1346-8138.2011.01384.x

20. Byrd JA, Davis MD, Rogers RS. "Recalcitrant symptomatic vulvar lichen planus: response to topical tacrolimus." Arch Dermatol. 2004;140(6):715–720. doi:10.1001/archderm.140.6.715

21. Kyriakou A, Patsatsi A, Patsialas C, Sotiriadis D. "Therapeutic efficacy of topical calcineurin inhibitors in plasma cell balanitis: case series and review of the literature." Dermatology. 2014;228(1):18–23. doi:10.1159/000357153

22. Moreno-Arias GA, Camps-Fresneda A, Llaberia C, Palou-Almerich J. "Plasma cell balanitis treated with tacrolimus 0.1%." Br J Dermatol. 2005;153(6):1204–1206. doi:10.1111/j.1365-2133.2005.06945.x

23. Amiri D, Schwarz CW, Gether L, Skov L. "Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review." Acta Derm Venereol. 2023;103:adv00890. doi:10.2340/actadv.v103.6525

24. Armstrong AW, Read C. "Pathophysiology, clinical presentation, and treatment of psoriasis: a review." JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006

25. Schauber J, Weisenseel P, Ruzicka T. "Topical treatment of perianal eczema with tacrolimus 0.1%." Br J Dermatol. 2009;161(6):1384–1386. doi:10.1111/j.1365-2133.2009.09345.x

26. Yosipovitch G, Bernhard JD. "Chronic pruritus." N Engl J Med. 2013;368(17):1625–1634. doi:10.1056/NEJMcp1208814

27. Mishra NN, Riedl C, Shah S, Pathak N. "Intravesical tacrolimus in treatment of intractable interstitial cystitis/bladder pain syndrome — a pilot study." Int J Urol. 2019;26(Suppl 1):68–72. doi:10.1111/iju.13978

28. Buford K, Peters KM, Riedl C, et al. "Global consensus on interstitial cystitis/bladder pain syndrome: an update on therapeutic treatments." Neurourol Urodyn. 2025. doi:10.1002/nau.70106

29. Di XP, Luo DY, Jin X, et al. "Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis." Int Urogynecol J. 2021;32(5):1129–1141. doi:10.1007/s00192-020-04659-w

30. Giannantoni A, Bini V, Dmochowski R, et al. "Contemporary management of the painful bladder: a systematic review." Eur Urol. 2012;61(1):29–53. doi:10.1016/j.eururo.2011.07.069

31. Elad S, Or R, Resnick I, Shapira MY. "Topical tacrolimus — a novel treatment alternative for cutaneous chronic graft-versus-host disease." Transpl Int. 2003;16(9):665–670. doi:10.1007/s00147-003-0594-2

32. Rostagno E, Campanati A, Mordini N, et al. "Phototherapy and topical treatments for cutaneous graft-vs-host disease in haematopoietic stem cell transplantation patients: a scoping review." J Eur Acad Dermatol Venereol. 2022;36(7):1003–1015. doi:10.1111/jdv.18074

33. US Food and Drug Administration. Tacrolimus topical — prescribing information and GVHD caution. Updated 2026-04-15.

34. Olson KA, West K, McCarthy PL. "Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant recipients with cutaneous graft-versus-host disease." Pharmacotherapy. 2014;34(6):e60–e64. doi:10.1002/phar.1418